Subacute cutaneous lupus erythematosus

  • M. N. Manoussakis
  • H. M. Moutsopoulos


Subacute cutaneous lupus erythematosus (SCLE) represents a relatively distinct and homogeneous subset of lupus erythematosus (LE) identified by chronic and recurrent development of characteristic erythematous, non-scarring and mostly photosensitive skin lesions associated with particular clinical, immunological and genetic features. SCLE-specific cutaneous lesions include the papulosquamous—psoriasiform eruption and the annular-polycyclic erythema. These are found in approximately 10% of total LE patients and affect predominantly white Caucasian women of all ages. In addition, a significant proportion of patients with SCLE eruptions may have Sjögren’s syndrome (SS). Extracutaneous manifestations are usually, but not always, mild. Serum autoantibodies to Ro (SSA) cellular antigen that occur in approximately 25-30% of total systemic lupus erythematosus (SLE) patients, are more common in SCLE (found in 60-70%) suggesting that SCLE comprises roughly 30-40% of all anti-Ro (SSA) positive patients. Approximately 50% of anti-Ro (SSA) positive SCLE patients display also serum anti-La (SSB) antibodies. Associations of SCLE with HLA-DR3, HLA-DR2 as well as C4 null alleles have been also reported. Finally, besides SLE and SS, a number of other systemic diseases that have been described to precede, to coincide with or to follow the onset of SCLE include rheumatoid arthritis (RA), porphyria cutanea tarda, Sweet’s syndrome, malabsorption, gluten-sensitive enteropathy, hereditary angioedema and various malignancies, including malignant melanoma, lung, breast and gastric cancer.


Hereditary Angioedema Porphyria Cutanea Tarda Discoid Lupus Erythematosus Subacute Cutaneous Lupus Erythematosus Betamethasone Dipropionate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Further reading

  1. Chlebus E, Wolska H, Blaszczyk M, Jablonska S. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 1998; 38: 405–12.PubMedCrossRefGoogle Scholar
  2. Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin N Am 1995; 21: 99–115.Google Scholar
  3. Fenton DA, Black MM. Low-dose dapsone in the treatment of subacute cutaneous lupus erythematosus. Clin Exp Dermatol 1986; 11: 102–3.PubMedCrossRefGoogle Scholar
  4. Fumer BB. Treatment of subacute cutaneous lupus erythematosus. Int J Dermatol 1990; 29: 542–7.CrossRefGoogle Scholar
  5. Maddison PJ. Nature and nurture in systemic lupus erythematosus. Adv Exp Med Biol 1999; 455: 7–13.PubMedCrossRefGoogle Scholar
  6. Naafs B, Bakkers EJM, Flinterman J, Faber WR. Thalidomide treatment of subacute cutaneous lupus erythematosus. Br J Dermatol 1982; 107: 83–6.PubMedCrossRefGoogle Scholar
  7. Ruzicka T, Sommerburg C, Goerz G, Kind P, Mensing H. Treatment of cutaneous lupus erythematosus with acitretin and hydroxychloroquine. Br J Dermatol 1992; 127: 513–18.PubMedCrossRefGoogle Scholar
  8. Sontheimer RD, Provost TT. Cutaneous manifestations of lupus erythematosus. In: Wallace DJ, Hahn BH, eds. Dubois’ Lupus Erythematosus, 5th edn. Baltimore: Williams and Wilkins, 1997: 569–623.Google Scholar
  9. Wallace DJ. Occasional, innovative and experimental therapies. In: Wallace DJ, Hahn BH, eds. Dubois’ Lupus Erythematosus, 5th edn. Baltimore: Williams and Wilkins, 1997: 1191–1202.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. N. Manoussakis
  • H. M. Moutsopoulos

There are no affiliations available

Personalised recommendations